StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.70+0.80 (+5.03%)

Close on Nov 17, 2026Market cap $1.65BP/E –Yield –

Ultragenyx Pharmaceutical operating margin

Operating margin is operating income as a percentage of revenue.

Ultragenyx Pharmaceutical's operating margin for the twelve months ending Jun 30, 2026 was -73.6%. For fiscal 2025 it was -79.5%, against -95.7% the year before. The highest annual figure on record is -79.5% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-79.5%+16.2
FY2024Dec 31, 2024-95.7%+35.4
FY2023Dec 31, 2023-131.1%+47.5
FY2022Dec 31, 2022-178.6%−70.0
FY2021Dec 31, 2021-108.6%+13.2
FY2020Dec 31, 2020-121.8%+287.2
FY2019Dec 31, 2019-409.0%+312.2
FY2018Dec 31, 2018-721.2%+11872.3
FY2017Dec 31, 2017-12593.5%+173877.9
FY2016Dec 31, 2016-186471.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-35.0%+29.6
Q1 FY2026Mar 31, 2026-124.3%−21.4
Q4 FY2025Dec 31, 2025-54.7%+19.6
Q3 FY2025Sep 30, 2025-106.9%−12.2
Q2 FY2025Jun 30, 2025-64.7%+14.5
Q1 FY2025Mar 31, 2025-102.9%+49.0
Q4 FY2024Dec 31, 2024-74.3%+21.5
Q3 FY2024Sep 30, 2024-94.6%+53.4
Q2 FY2024Jun 30, 2024-79.1%+57.5
Q1 FY2024Mar 31, 2024-151.9%+1.4
Q4 FY2023Dec 31, 2023-95.8%+45.1
Q3 FY2023Sep 30, 2023-148.0%+100.2
Q2 FY2023Jun 30, 2023-136.6%+21.9
Q1 FY2023Mar 31, 2023-153.3%+17.6
Q4 FY2022Dec 31, 2022-140.9%−17.9
Q3 FY2022Sep 30, 2022-248.1%−138.1
Q2 FY2022Jun 30, 2022-158.5%−63.3
Q1 FY2022Mar 31, 2022-170.9%−63.7
Q4 FY2021Dec 31, 2021-123.0%−18.0
Q3 FY2021Sep 30, 2021-110.0%−48.3
Q2 FY2021Jun 30, 2021-95.2%+7.0
Q1 FY2021Mar 31, 2021-107.2%+225.1
Q4 FY2020Dec 31, 2020-105.0%+160.4
Q3 FY2020Sep 30, 2020-61.8%+395.7
Q2 FY2020Jun 30, 2020-102.2%+363.6
Q1 FY2020Mar 31, 2020-332.3%+213.6
Q4 FY2019Dec 31, 2019-265.4%+290.2
Q3 FY2019Sep 30, 2019-457.5%+304.6
Q2 FY2019Jun 30, 2019-465.8%+276.0
Q1 FY2019Mar 31, 2019-546.0%+357.7
Q4 FY2018Dec 31, 2018-555.6%+3455.8
Q3 FY2018Sep 30, 2018-762.1%+41517.2
Q2 FY2018Jun 30, 2018-741.8%+1410238.2
Q1 FY2018Mar 31, 2018-903.7%+58360.3
Q4 FY2017Dec 31, 2017-4011.4%–
Q3 FY2017Sep 30, 2017-42279.3%–
Q4 FY2016Dec 31, 2016-1410980.0%–
Q3 FY2016Sep 30, 2016-59264.0%–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?